Clinical monitoring is the primary mechanism through which a sponsor maintains control over study conduct. Every data point that reaches your database, every protocol deviation that gets caught in time, every inspection that passes without a critical finding – these outcomes trace back to how monitoring was set up, resourced, and integrated with your broader operations.
If you are running a Phase II or Phase III study in Europe and your CRO is treating monitoring as a standalone activity – visiting sites, producing reports, and filing them – you are not getting what monitoring is supposed to deliver. You are getting documentation. What you need is oversight.
APICES delivers clinical monitoring as a control function embedded in your clinical operations team, not as a reporting service. Our clinical research associates are senior, therapeutically experienced, and part of the same operational structure as your project managers, data managers, and safety monitors. That integration is not a description of collaboration; it is the mechanism that keeps issues from escalating.
Our approach to clinical monitoring is built on the ICH E6(R3) risk-based framework, but the implementation goes beyond compliance. Monitoring plans are designed around your specific protocol, country setup, and risk profile – not copied from a previous study. Site visit frequency, source data verification scope, and central monitoring thresholds are calibrated together, with input from the study team, not set in isolation by a monitoring lead.
CRAs at APICES carry an average of seven or more years of site-facing experience. For oncology and rare disease studies, therapeutic-area training is mandatory before the first site visit. We do not staff junior CRAs on first-in-human or pivotal programs, and we do not substitute seniority with a monitoring management layer.
Where on-site monitoring is required, our CRAs conduct source data verification against the critical data points defined in the monitoring plan – not 100 percent SDV for its own sake. Where remote monitoring can reduce site burden and cost without sacrificing oversight, it is built in from the start. Central monitoring runs in parallel: safety signals, enrollment trends, and protocol deviation patterns are reviewed at the study level on a defined cadence.
Monitoring findings are not managed in isolation. Issues identified at site level are communicated immediately to project management, data management, and safety, and resolved with full context. This is the difference between a monitoring system that catches problems and one that actually prevents them from recurring.
Many CROs quote senior CRAs in proposals and staff junior ones in delivery. At APICES, the CRA who visits your sites is the same one named in your monitoring plan. We have CRAs based in Spain, France, Germany, Italy, the Netherlands, the UK, and selected experience in Belgium, Portugal, and Poland – covering the markets where your study is most likely to run.
CRA-to-site ratios are defined in the monitoring plan before study start-up and reviewed at each governance milestone. If a site increases in complexity – due to slow enrollment, high deviation rate, or a change in site staff – the monitoring approach adapts. Sponsors are notified through the standard reporting structure, not after the fact.
Inspection readiness is built into how APICES monitors, not added as a separate preparation phase. Risk indicator tracking, deviation documentation, and audit trail review are standard components of the monitoring rhythm. By the time a regulatory inspection is announced, the documentation trail is already coherent – because it was built that way from the first monitoring visit.
This matters particularly for Phase III pivotal programs and studies in therapeutic areas with high regulatory scrutiny, such as oncology, rare disease, and ATMP development. A robust monitoring record is not just an operational asset; it is a regulatory asset.
What does APICES's clinical monitoring service include?
Risk-based monitoring under ICH E6(R3): site qualification, initiation, routine on-site and remote monitoring, source data verification, central monitoring, close-out, and inspection-readiness preparation. We staff senior CRAs and a clinical operations lead per study.
Do you do risk-based or 100% SDV monitoring?
Both, depending on protocol risk and sponsor preference. Most studies use a risk-based model with targeted SDV on critical data points and central monitoring on safety and trends, in line with ICH E6(R3) Annex A.
Are CRAs senior or junior?
Our CRAs are senior – typically 7+ years of monitoring experience, therapeutic-area trained for oncology and rare-disease studies. We do not staff junior CRAs on first-in-human or pivotal studies.
Can you provide CRAs in specific countries?
Yes. We have CRAs based in Spain, France, Germany, Italy, the Netherlands, the UK, and selected experience in Belgium, Portugal, and Poland. We staff country-by-country to match site language and regulatory familiarity.
How do you handle inspection readiness?
Continuously, not last-minute. Risk indicators, deviation tracking, and audit-trail review are part of the monitoring rhythm – so when an inspector arrives, the trail is already coherent.
If you are preparing your next early clinical study or want to sanity-check how your program is set up, the next step is a focused conversation.
No packaged answers. Just context, experience, and a clear view on fit.
